Sandy Srinivas
Academic Appointments
- Associate Professor - Med Center Line, Medicine - Oncology
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Uro-Oncology Clinic 875 Blake Wilbur Dr Clinic E Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 736-1640
- Academic Offices
Personal Information Email Tel (650) 724-8372 Tel (650) 725-2078Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Urologic Oncology
- Bladder Cancer
- Bladder Cancer - Medical Oncology
- Germ Cell Tumors
- Germ Cell Tumors - Medical Oncology
- Germ Cell Tumors - Urologic Oncology
Administrative Appointments
- Prostate Panel member, NCCN (2002 - present)
- DSMC Vice Chair, Stanford University (2002 - present)
Honors and Awards
- Oncology Clinical Fellows Teaching award, Stanford University (2009)
- Oncology Clinical Fellows Teaching award, Stanford University (2008)
- Oncology Clinical Fellows teaching award, Stanford University (2007)
- Oncology Clinical Fellows Teaching award, Stanford University (2006)
- Oncology Clinical Fellows Teaching award, Stanford University (2005)
- Oncology Clinical Fellows teaching award, Stanford University (2004)
Professional Education
| Board Certification: | Medical Oncology, American Board of Internal Medicine (1997) |
| Residency: | St. Mary's Hospital - New York NY (1991) |
| Medical Education: | Madras University Medicine, India (1985) |
| Fellowship: | UCSF Medical Center CA (1994) |
| Internship: | St. Mary's Hospital - New York NY (1991) |
Graduate & Fellowship Program Affiliations
Industry Relationships
Stanford is committed to ethical and transparent interactions with our industrial and other commercial partners. It is our policy to disclose payments (exclusive of travel support) from, and/or equity in, companies or other commercial entities to Stanford faculty of $5,000 or more in total value, as well as any equity in a privately held company, when the faculty member also has institutional responsibilities related to his or her interactions with the company. View Full Information
Scientific Focus
Current Research Interests
The Genito-Urinary Multidisciplinary tumor board at Stanford specalizes in taking care of patients with prostate cancer, renal cancer, testicular and bladder cancer. Patients are seen at different stages of their tumor. A multisdiscplinary approach is used. A variety of clinical trials are available to patients. Phase II trials using unique combination of chemotherapy agents, antiangiogenic drugs, novel agents are being explored.Co-operative group particpation through ECOG is also available
Clinical Trials
- Recruiting Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
- Recruiting Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot be Removed by Surgery
- Recruiting Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
- Recruiting Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
- Not Recruiting F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
Publications
- A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2013; (2): 100-6
- Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013; (4): 412-9
- Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013; (2): 181-6
- Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC). Urol Oncol. 2013; (3): 379-85
- Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013; (1): 215-24
- Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol. 2012; (9): 927-35
Help
Trial Administration